Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
3E Bioventures Capital
Palo Alto, California, United States3ebiovc.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
3E Bioventures Capital is a science-driven, entrepreneur-friendly VC investing in life science innovations with active portfolio programs spanning preclinical to late stage clinical development, including first-in-class and best-in-class biologics, small molecules, and platform technologies
- Therapeutic areas
- ImmunologyNephrologyMetabolic DisordersOphthalmologyInfectious DiseasesRare DiseasesDermatologyOtherOncologyNeurology
- Modalities
- Small moleculeBiologicGene therapyAntibodyAntibody-drug conjugateProteinRecombinant proteinPeptidesMacrocyclesDrug delivery systemDeviceLipid nanoparticle delivery therapy
- Industry
- Investors
02
Partnerships
SDIC Venture CapitalBioVeda China FundMorningside GroupCMB International Capital CorporationWuXi Healthcare VenturesShangbay CapitalVT VenturesTasly Pharmaceutical
Beyond the preview
Go deeper on 3E Bioventures Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3E Bioventures Capital.